Results 161 to 170 of about 99,677 (264)

Effect of IL-6 receptor inhibition on infarct volume after endovascular treatment for ischaemic stroke: a phase 2, randomised, placebo-controlled trial. [PDF]

EBioMedicine
Chu X, Lan J, Ma Z, Yin Y, Gu H, Baron JC, Liesz A, Wen C, Liu Y, Sun J, Wang N, Li C, Feng X, Li J, Wang B, Feng Y, Wu C, Dong X, Zhou C, Li C, Zhao W, Liu G, Fisher M, Liebeskind DS, Fang M, Jia X, Ma H, Ji X, Wu C, IRIS investigators.   +29 more
europepmc   +1 more source

Performance of Circulating Inflammatory Biomarkers and Krebs von den Lungen 6 for Predicting Progressive Pulmonary Fibrosis in Patients With Systemic Sclerosis–Associated Interstitial Lung Disease

ACR Open Rheumatology, Volume 8, Issue 3, March 2026.
Objective To assess the predictive performance of inflammatory biomarkers, including C‐reactive protein (CRP) and Krebs von den Lungen 6 (KL‐6), for the development of progressive pulmonary fibrosis (PPF) in patients with systemic sclerosis (SSc)–associated interstitial lung disease (ILD).
Keina Yomono, Suiyuan Huang, Dinesh Khanna, Masataka Kuwana   +3 more
wiley   +1 more source

Severe neuro-behçet's disease refractory: Radiologic improvement with tocilizumab. [PDF]

Radiol Case Rep
Benyarou K, El Hasnaoui S, Yousfi S, Mebrouk Y.   +3 more
europepmc   +1 more source

Tocilizumab as a key therapeutic option in high-risk pediatric acute necrotizing encephalopathy. [PDF]

Clin Exp Pediatr
Kim JS.
europepmc   +1 more source

PBRM1 Deficiency Reshapes an Immune Suppressive Microenvironment Through Epigenetic Tuning of PBRM1‐KDM5C‐IL6 Axis in ccRCC

Advanced Science, Volume 13, Issue 16, 18 March 2026.
PBRM1 ranks as the second most commonly mutated gene in ccRCC. This study reveals that PBRM1 loss promotes an immunosuppressive microenvironment by elevating M2 TAMs via the KDM5C–IL‐6 axis. These M2 TAMs, along with CAFs, form a barrier that excludes CD8+ T cells. Targeting IL‐6 synergizes with anti‐PD1 therapy, offering a promising strategy for PBRM1‐
Wenjiao Xia, Hongru Wang, Yu Dong, Zitong Yang, Yiyang Zhou, Zhinan Xia, Qinchen Li, Liangliang Ren, Yichun Zheng, Junliang Yan, Dongmei Ma, Zhi Chen, Xingang Cui, Guixin Zhu, Cheng Zhang   +14 more
wiley   +1 more source

Prompt clinical and electrophysiological remission of refractory peripheral neuropathy in long-standing rheumatoid arthritis with tocilizumab: a case report. [PDF]

Front Immunol
Huang H, Zhong X, Kuang S, Tan J, Tan L, Li B.   +5 more
europepmc   +1 more source

Cytokine‐Engineered Chimeric Antigen Receptor‐T Cell Therapy: How to Balance the Efficacy and Toxicity

Advanced Science, Volume 13, Issue 14, 9 March 2026.
Cytokine‐engineered CAR‐T cells represent a promising immunotherapy against malignancies due to direct tumor killing and potent immunity response. However, significant toxicities, including CRS and ICANS, have restricted clinical applications. How to keep the risk‐benefit balance of the advanced therapy is of great importance for maximizing the benefit
Xinru Zhang, Gulizeba Aimaiti, Yuanye Guan, Yuzhe Sha, Wei Zhou, Jiefeng Shen, Bo Zhao, Wei‐En Yuan   +7 more
wiley   +1 more source

Safety and preliminary efficacy of adding tocilizumab to cisplatin/docetaxel for the treatment of locally advanced triple-negative breast cancer patients: prospective phase 1/2 clinical trial. [PDF]

Sci Rep
Al-Tweigeri T, Tulbah A, Akhtar S, Alzahrani M, Najjar S, El Hassan T, Alraouji NN, Suleman K, AlSayed A, Aboussekhra A.   +9 more
europepmc   +1 more source

Longitudinal plasma interleukin‐6 and post‐stroke cognitive outcomes: The Stroke‐IMPaCT study

Alzheimer's &Dementia, Volume 22, Issue 3, March 2026.
Abstract INTRODUCTION Inflammatory factors, particularly interleukin (IL)‐6, are implicated in post‐stroke cognitive decline, yet the association with longitudinal changes in these markers remains unclear. METHODS Plasma IL‐6 and other inflammatory markers were measured within 96 hours of ischemic stroke, and at 6–9 and 18–21 months, alongside ...
Natasha S. Carmichael, Harry R. Deijnen, Siew Yan Wong, Thomas O. Williams, Evangelos Kontopantelis, Luke Cowie, Eileen Jones, Lauren Drag, Marion S. Buckwalter, John R. Grainger, Stuart M. Allan, Craig J. Smith   +11 more
wiley   +1 more source

Incidence and risk factors of tocilizumab-induced hypofibrinogenemia in patients with thyroid eye disease: a single-center retrospective study. [PDF]

Front Endocrinol (Lausanne)
Wang E, Hu Q, Xu S, Zhou J, Wang J, Song Z, Wang X.   +6 more
europepmc   +1 more source